GLP-1 medications
GLP-1 is a hormone your gut releases after you eat — it tells your brain you're full and helps your body manage blood sugar. GLP-1 medications (semaglutide, tirzepatide, and newer molecules) copy that signal, which is why they're so widely studied for weight management and metabolic health.
The articles below explain how these medications work, what the research actually shows, and what side effects and dosing schedules look like in practice. Promise offers compounded GLP-1 medications by prescription only: a licensed provider reviews every request, and not everyone qualifies.
331 articles on this topic
-

Acmopatide Type 1 Diabetes: Small Blood Sugar Drop
A 111-person trial found weight loss and a small blood sugar change alongside insulin. Roche had already announced that development would stop.
-

GLP-1 Liver Cancer Study: Prevention Is Unproven
A new study found lower liver-cancer rates in people with diabetes and viral hepatitis. It doesn't prove prevention or apply to every GLP-1 user.
-

Does Semaglutide Cause Bone Loss? What We Know
Bone density can fall during semaglutide-related weight loss. New reviews and the Wegovy label explain why fracture risk needs a more individual answer.
-

Bariatric Surgery After GLP-1: A Next Option
A new Cleveland Clinic study followed people who didn't tolerate semaglutide or tirzepatide, or lost little weight. Surgery remained a possible next step.
-

Does Ozempic Make You Drink Less? Survey Findings
About 44% of drinkers in a national survey reported drinking less after starting a GLP-1 medicine. The study cannot show that Ozempic caused the change.
-

GLP-1 for Prediabetes: What the New Study Found
A large health-record study linked GLP-1 medicines with better blood-sugar outcomes than metformin. Its early results don't settle which medicine fits you.
-

Does Medicaid Cover Weight Loss Drugs? 1990 to Now
States can choose to cover weight-loss medicines. The framework began in 1990; the explicit weight-loss wording followed in 1993.
-

Retatrutide Knee Osteoarthritis: What TRIUMPH-4 Found
Lilly's November 5 preview reports less knee pain in two retatrutide trials. The dose, placebo comparison and analysis behind each headline matter.
-

Can You Take Ibuprofen With Tirzepatide? Key Risks
The labels don't name ibuprofen as an interaction. Dehydration, kidney disease, ulcers, and other medicines can still change the answer.
-

Semaglutide Alcohol Use Disorder Trial: Results
A 48-person trial found less drinking on some measures and lower cravings. It did not establish lasting recovery or a treatment plan for alcohol use disorder.
-

Does Semaglutide Cause Erectile Dysfunction?
Erection problems have been reported during semaglutide treatment, but a direct cause hasn't been established. Labels and studies tell different parts of the story.
-

What Is a Salt Form of a Drug? Names Explained
A salt form pairs a drug's active molecule with a charged partner. That can change its physical properties without establishing that different forms are interchangeable.
-

Ozempic Nails: What the 2026 GLP-1 Nail Study Found
A new October 2026 dermatology survey linked GLP-1 use to higher self-reported nail detachment. Here is what the study actually measured, why U.S. drug labels list no nail disorders, and when a lifted nail needs a doctor.
-

Stomach Bug on Ozempic or Zepbound: What the Labels Say
Vomiting and diarrhea from a winter virus can drain fluids fast when you take a GLP-1 medication. Here is how the official labels handle dehydration warnings, missed doses, and calling your doctor.
-

Tirzepatide Bloating: Trial Rates and Warning Signs
Tirzepatide can cause a full or swollen belly, though clinical trials recorded visible abdominal distension in 3% to 4% of weight-management patients. Here is what the brand labels report, why slowed digestion plays a role, and which symptoms need a doctor right away.
-

Revita GLP-1 Results: Less Regain After Stopping
A six-month study found less weight regain after tirzepatide ended. The procedure is still investigational, and the one-year result is pending.
-

Ozempic Before Colonoscopy: Do You Need to Stop?
Taking Ozempic before a colonoscopy does not mean an automatic pause for every patient. Your prescriber and endoscopy team weigh stomach emptying, bowel prep quality, and your symptoms to set your plan.
-

CagriSema Menopause: Weight Loss Across Stages
Women lost weight across menopause stages in a new CagriSema analysis. The headline estimate assumes continued treatment, and the stage comparisons leave questions open.
-

Retatrutide Sleep Apnea: Fewer Breathing Events
Two 80-week trials found fewer breathing interruptions with retatrutide. The results don't show it beats tirzepatide or replaces airway treatment.
-

ACOG GLP-1 Guidance: Pregnancy and Breastfeeding
ACOG advises against GLP-1 use during pregnancy. Its new breastfeeding guidance allows an individual care plan, with firm limits for newborn and premature infants.
Page 3 of 17 · 331 articles